Big Retailers Report
Good Morning Everyone!
Customers are setting banks on fire in Lebanon because they can’t get their money out.
Inflation is at +170%.
This is what a currency collapse looks like:
Earnings Scheduled For February 21, 2023
Companies Reporting Before The Bell
• Sohu.com (NASDAQ:SOHU) is likely to report earnings for its fourth quarter.
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Reported Late Friday, Harmony Biosciences Appoints Jeffrey M. Dayno, MD As Interim CEO And Expands Role Of Jeff Aronin To Executive Chairman
Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare
Mizuho Maintains Buy on Harmony Biosciences, Raises Price Target to $70
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $60 to $70.
Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $65
Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $60 to $65.
Gartner, Sony, Uber And Other Big Gainers From Tuesday
U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session.
Recap: Harmony Biosciences Q3 Earnings
Harmony Biosciences (NASDAQ:HRMY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Harmony Biosciences posted an EPS of $0.95.
Harmony Biosciences Announces Topline Results From Phase 2 Proof-of-concept Study Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willii Syndrome
Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today
Where Harmony Biosciences Stands With Analysts
Analysts have provided the following ratings for Harmony Biosciences (NASDAQ:HRMY) within the last quarter: